Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage

Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Aug 15, 2022

Keywords

ClinConnect Summary

This clinical trial is looking to find a specific treatment target for patients who have experienced an acute, spontaneous bleeding in the brain, known as an intracerebral hemorrhage (ICH). The goal is to see if a certain type of therapy that is delivered through blood vessels (called endovascular therapy) could be beneficial for these patients. The study is currently recruiting participants aged 65 to 74 who have been diagnosed with ICH and are within three hours of their symptoms starting.

To be eligible for the trial, participants must have a confirmed diagnosis of ICH through a type of brain scan called a CT scan. They also need to have the agreement of their doctor to undergo a special imaging procedure known as digital subtraction angiography (DSA). However, individuals who have certain conditions, such as a high chance that their bleeding is due to specific causes like an aneurysm or who are pregnant, will not be eligible. Participants in the trial can expect to undergo DSA to help determine the best treatment options for their condition, and their safety will be closely monitored throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of an acute spontaneous ICH based on non-contrast CT
• • Time from symptom onset to anticipated start of cerebral DSA of under 3 hours
• • Agreement of the treating physician to perform DSA
• • Informed consent documented by signature or fulfilling the criteria for emergency consent procedures (deferral of consent)
• Exclusion Criteria:
• • High probability that the etiology of the bleeding is a ruptured aneurysm, an arteriovenous malformation or an amyloid angiopathy as judged by the treating physician
• • Any time critical surgical or minimal invasive intervention is planned
• • Evidence of an ongoing pregnancy, a negative pregnancy test is mandatory in all persons of childbearing potential
• • Contraindications against the use of iodine contrast media
• • Known severe kidney insufficiency (Glomerular filtration rate \< 30 ml/min)